A simple, specific, accurate, and stability-indicating reversed-phase high-performance liquid chromatographic method was developed for the simultaneous determination of montelukast and fexofenadine hydrochloride, using a Lichrospher® 100, RP-18e column and a mobile phase composed of methanol:0.1% o-phosphoric acid (90:10 v/v), pH 6.8. The retention times of montelukast and fexofenadine hydrochloride were found to be 10.16 and 12.03 min, respectively. Linearity was established for montelukast and fexofenadine hydrochloride in the range of 2-10 μg/ml and 24-120 μg/ml, respectively. The percentage recoveries of montelukast and fexofenadine hydrochloride were found to be in the range of 99.09 and 99.81%, respectively. Both the drugs were subjected to acid and base hydrolysis, oxidation, photolytic, and thermal degradation conditions. The degradation products of montelukast and fexofenadine hydrochloride were well resolved from the pure drug with significant differences in their retention time values. This method can be successfully employed for simultaneous quantitative analysis of montelukast and fexofenadine hydrochloride in bulk drugs and formulations.

Aim: Antiurolithiatic activity of magnesium lactate gluconate (MLG) and aqueous extract of Garcinia cambogia (GC) fruit was studied. Materials and Methods: The study was performed during December 2016 to April 2017. Urolithiasis was induced in male Wistar rats by administration of 0.75% v/v ethylene glycol for 21 days. From 8 th day onward, intervention with MLG (200 and 400 mg/kg b.w.) and GC (100 and 200 mg/kg b.w.) was started. At the end of the treatment period, biochemical parameters affecting renal stone formation were estimated in the serum, urine, kidney homogenate, and histopathology of harvested kidneys was performed. Results: From in vivo evaluation, it was observed that MLG 400 mg/kg b.w., GC 100 mg/kg b.w., and GC 200 mg/kg b.w. significantly reduced nitrogenous waste products in serum (blood urea nitrogen, creatinine, and uric acid) as well as calculogenic promoters in urine (phosphate and oxalate) and kidney homogenate (calcium, phosphate, and oxalate) when compared to disease control animals. The MLG 200 and MLG 400 were ineffective in restoring superoxide dismutase (SOD) and catalase (CAT) enzyme activity, whereas GC 100, GC 200, and Cystone ® 400 mg/kg b.w. significantly elevated SOD and CAT enzymes in urolithiatic rat kidney. Conclusions: MLG and GC extracts are capable of preventing calcium oxalate (CaOx) crystal formation and subsequent deposition in renal tubules. The principle mechanism underlying nephroprotective effect of test drugs might be attributed to their calcium ion chelating ability and CaOx crystallization inhibitory activity. It is further asserted that GC was more potent than MLG in overall kidney protection by virtue of its antioxidant potential.

No abstract

No abstract